Thyroid cancer is the most common endocrine malignancy and it accounts for 1% of all
newly diagnosed tumors. Approximately 10% of patients with differentiated thyroid …

Driven by the intricacy of the illness and the need for individualized treatments, targeted
therapy and biomarker research in thyroid cancer represent an important frontier in …

Differentiated thyroid carcinomas (DTCs) that arise from follicular cells account> 90% of
thyroid cancer (TC)[papillary thyroid cancer (PTC) 90%, follicular thyroid cancer (FTC) 10%] …

10 Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of
BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the …

For differentiated thyroid cancer (DTC), systemic therapy with radioactive iodine (RAI) is
utilized for radiosensitive disease, while for radioiodine refractory (RAIR) disease, current …

Objective To review the emerging evidence that therapies targeting key oncogenic and
signaling kinases can be effective in treatment of advanced thyroid carcinomas. Methods …

Thyroid cancers (TCs) are the most common tumors of the endocrine system and a constant
rise in the number of TC cases has been observed for the past few decades. TCs are one of …

Advanced thyroid carcinoma is an infrequent tumor entity with limited treatment possibilities
until recently. The extraordinary improvement in the comprehension of genetic and …

The treatment of advanced, radioiodine refractory, differentiated thyroid cancers (RR-DTCs)
has undergone major advancements in the last decade, causing a paradigm shift in the …

Differentiated thyroid carcinoma (DTC) accounts for more than 90% of new thyroid cancer
diagnoses, and includes papillary, follicular and Hürthle cell carcinoma. The prognosis for …